Cost‐effectiveness of a new urinary biomarker‐based risk score compared to standard of care in prostate cancer diagnostics–a decision analytical model
S Dijkstra, TM Govers, RJ Hendriks… - BJU …, 2017 - Wiley Online Library
Objective To assess the cost‐effectiveness of a new urinary biomarker‐based risk score
(Select MD x; MD xHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(Select MD x; MD xHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
[PDF][PDF] Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics–a decision analytical model
S Dijkstra, TM Govers, RJ Hendriks, JA Schalken… - 2017 - academia.edu
Objective To assess the cost-effectiveness of a new urinary biomarkerbased risk score
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics-a decision analytical model.
S Dijkstra, TM Govers, RJ Hendriks… - BJU …, 2017 - search.ebscohost.com
Objective To assess the cost-effectiveness of a new urinary biomarker-based risk score
(Select MDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(Select MDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics-a decision analytical model
S Dijkstra, TM Govers, RJ Hendriks… - BJU …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective To assess the cost-effectiveness of a new urinary biomarker-based risk score
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics-a decision analytical model
S Dijkstra, TM Govers, RJ Hendriks… - BJU …, 2017 - cris.maastrichtuniversity.nl
ObjectiveTo assess the cost-effectiveness of a new urinary biomarker-based risk score
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics: a decision analytical model
S Dijkstra, TM Govers, RJ Hendriks… - BJU …, 2017 - biblio.ugent.be
Objective: To assess the cost-effectiveness of a new urinary biomarker-based risk score
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics: a decision analytical model
S Dijkstra, TM Govers, RJ Hendriks, JA Schalken… - BJU …, 2017 - lib.ugent.be
Objective: To assess the cost-effectiveness of a new urinary biomarker-based risk score
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics-a decision analytical model.
S Dijkstra, TM Govers, RJ Hendriks, JA Schalken… - BJU …, 2017 - europepmc.org
Objective To assess the cost-effectiveness of a new urinary biomarker-based risk score
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
[引用][C] Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics-a decision analytical model
S Dijkstra, TM Govers, RJ Hendriks, JA Schalken… - 2017 - repository.ubn.ru.nl
OBJECTIVE: To assess the cost-effectiveness of a new urinary biomarker-based risk score
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
[PDF][PDF] Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics–a decision analytical model
S Dijkstra, TM Govers, RJ Hendriks, JA Schalken… - 2017 - academia.edu
Objective To assess the cost-effectiveness of a new urinary biomarkerbased risk score
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …
(SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …